Partner Content Partner Content STORM Therapeutics Joins SMi’s 9th Annual RNA Therapeutics STORM Therapeutics Exclusive Speaker Interview
News Norgine gets first EU approval for WHIM syndrome therapy Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
